Your session is about to expire
← Back to Search
Zibotentan + Dapagliflozin for Kidney Disease (ZODIAC Trial)
ZODIAC Trial Summary
This trial will test if two drugs given together can help reduce albuminuria (a protein in urine) more than either drug given alone.
ZODIAC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowZODIAC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ZODIAC Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are individuals of all ages being accepted for this study?
"This trial is open to patients aged 18-75. There are 43 similar trials for minors and 479 for seniors."
Might I be eligible to take part in this experiment?
"Up to 38 patients that have been diagnosed with chronic kidney disease (CKD) and meet the following additional requirements can participate in this clinical trial: age between 18-75 years old, a diagnosis of type 2 diabetes, Hba1c score above 6.0%, urinary albumin:creatinine ratio no more than 3500 mg/g in a first morning void urine collection, eGFR must be 30 mL/min/1.73m2 or higher, ACEi or ARB stable dose for at least 4 weeks before randomization, and being willing to sign informed consent."
Are we still enrolling patients for this clinical trial?
"Unfortunately, this particular study is no longer looking for patients to enroll. According to the information available on clinicaltrials.gov, recruitment for this trial ceased on October 18th, 2022; although there are 519 other trials currently recruiting individuals."
Are there any negative side effects associated with Treatment order 1?
"While efficacy has not been proven, there is evidence that suggests treatment order 1 is safe. We've given it a score of 2."
Share this study with friends
Copy Link
Messenger